Genmab A (GMAB) EPS (Weighted Average and Diluted): 2018-2021
- Genmab A's EPS (Weighted Average and Diluted) rose 358.09% to $1.97 in Q2 2021 from the same period last year, while for Jun 2021 it was $4.20, marking a year-over-year increase of 141.80%. This contributed to the annual value of $8.39 for FY2020, which is 137.04% up from last year.
- According to the latest figures from Q2 2021, Genmab A's EPS (Weighted Average and Diluted) is $1.97, which was up 111.17% from $0.93 recorded in Q4 2020.
- In the past 5 years, Genmab A's EPS (Weighted Average and Diluted) registered a high of $1.97 during Q2 2021, and its lowest value of $0.13 during Q2 2019.
- In the last 3 years, Genmab A's EPS (Weighted Average and Diluted) had a median value of $0.86 in 2019 and averaged $0.86.
- Data for Genmab A's EPS (Weighted Average and Diluted) shows a peak YoY skyrocketed of 358.09% (in 2021) over the last 5 years.
- Genmab A's EPS (Weighted Average and Diluted) (Quarterly) stood at $0.32 in 2018, then spiked by 169.49% to $0.86 in 2019, then increased by 8.47% to $0.93 in 2020, then surged by 358.09% to $1.97 in 2021.
- Its EPS (Weighted Average and Diluted) was $1.97 in Q2 2021, compared to $0.93 in Q4 2020 and $0.43 in Q2 2020.
